Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Britain Courts Anthropic Amid US Defense Department Dispute 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Apple Turns 50: From Garage Startup to AI Crossroads 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
NEW YORK, June 23, 2017 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Akari Therapeutics, Plc securities (NASDAQ:AKTX) from March 30, 2017 through May 11, 2017, both dates inclusive (the “Class Period”) of the important July 11, 2017 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Akari Therapeutics investors under the federal securities laws.
To join the Akari Therapeutics class action, go to http://www.rosenlegal.com/cases-1127.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Akari Therapeutics’s CEO, and possibly other executives, were involved in publishing false information about Akari Therapeutics, including false information about the Phase 2 PNH trial of Coversin; (2) Akari Therapeutics lacked adequate checks and protections to prevent such behavior; and (3) as a result, defendants’ statements about Akari Therapeutics’ business, operations, and prospects, were false and misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 11, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1127.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
